The drug is currently approved for the treatment of COVID, but only in a
hospital setting and for those patients who are already extremely ill.
Gilead's COVID-19 drug Remdesivir reduced serious illness and death by nearly 90% in a new study conducted by the company.
According to trial data, the participants received the drug intravenously on three consecutive days, outside a hospital setting.
The drug is currenty approved for the treatment of COVID, but only in a hospital setting and for those patients who are already extremely ill.
Gilead hopes this new data will persuade regulators to make their drug more widely available.
This drug can also be useful in preventing further hospitalizations from the Delta variant, paired with antibody treatments.
Both types of mitigation are in such high demand that the Biden Administration has rationed the drug as well as antibody treatments.
The drug company said it shared the new data with the FDA and the World Health Organization.
No comments:
Post a Comment